Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

53P - Second line treatment in advanced non-squamous (NS) non-small cell lung cancer (NSCLC) patients in Spain, analyzed in the Thoracic Tumor Registry (RTT)


03 Apr 2022


Poster Display session


Non-Small Cell Lung Cancer


Enric Carcereny Costa


Annals of Oncology (2022) 33 (suppl_2): S27-S70. 10.1016/annonc/annonc856


E. Carcereny Costa1, A. Collazo Lorduy2, M. Cobo Dols3, D. Rodriguez Abreu4, R. Bernabe Caro5, R. Lopez Castro6, B. Massuti Sureda7, E. del Barco8, M. Guirado9, J. Bosch-Barrera10, J.L. Gonzalez-Larriba11, A. Sanchez Hernandez12, O.J. Juan Vidal13, J.M. Oramas Rodriguez14, J. Mosquera Martinez15, A.L.O. Ortega Granados16, A. Padilla17, M.T. Moran Bueno18, A. Cantero19, M. Provencio Pulla20

Author affiliations

  • 1 ICO - Institut Català d'Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Badalona/ES
  • 2 University Hospital Puerta de Hierro Majadahonda, 28222 - Majadahonda/ES
  • 3 Biomedical Research Institute of Málaga (IBIMA), Malaga/ES
  • 4 Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria/ES
  • 5 Hospital Universitario Virgen del Rocio, 41013 - Sevilla/ES
  • 6 Hospital Clinico Universitario De Valladolid, 47003 - Valladolid/ES
  • 7 Hospital General Universitario de Alicante, Alicante/ES
  • 8 Hosp. Clinico Unversitario Salamanca, Salamanca/ES
  • 9 Hospital General Universitario de Elche, 3203 - Elche/ES
  • 10 ICO Girona - Institut Català d'Oncologia Girona, 17007 - Girona/ES
  • 11 Hospital Clinico Universitario San Carlos, Madrid/ES
  • 12 Consorcio Hospitalario Provincial de Castellón, Castellon de la Plana/ES
  • 13 Hospital Universitari i Politècnic La Fe, Valencia/ES
  • 14 Hospital Universitario de Canarias, San Cristobal de la Laguna/ES
  • 15 CHUAC - Complexo Hospitalario Universitario A Coruña, 15006 - A Coruña/ES
  • 16 Hospital Universitario de Jaén, Jaén/ES
  • 17 Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife/ES
  • 18 ICO - Institut Català d'Oncologia Badalona, 8916 - Badalona/ES
  • 19 Hospital Regional Universitario Málaga Carlos Haya, 29010 - Malaga/ES
  • 20 University Hospital Puerta de Hierro Majadahonda, Majadahonda/ES

Abstract 53P


Non-small cell lung cancer (NSCLC) accounts for the vast majority of all diagnosed lung cancers.


From a histological point of view, approximately 70% to 78% of NSCLC are considered non-squamous (NS). Our analysis aimed to describe the clinical, epidemiological characteristics and survival of Spanish patients suffering from advanced NS NSCLC, treated in second line included in the RTT of the Spanish Group of Lung Cancer.


2342 patients with advanced NS NSCLC in second line were included. The median age was 67 years. 63.4 % were men. 97% of them were White. 41.7% were former smokers and 35.7% were active smokers. ECOG performance status was 0 in 32.2% and 1 in 58.7%. Most common site of metastasis was lung in 41.7%, bone in 36%, and adrenal glands in 15.6% of patients. In overall population a median progression-free survival (PFS) time of 8.1 months (4.7-13.5 m) was observed. A median overall survival (OS) time of 22.1 m (11.6-45.8 m) A total of 145 (5.8%) patients had been treated with nintedanib (N). The median PFS for patients with N treatment was 8.3 months (5.6 - 16.2 months) and for patients without was 8.1 months (4.7 - 13.5). The probability of PFS at 6, 12 and 24 m was 66.1% (64.0% - 68.0%), 29.8% (27.8% - 31.7%) and 8.2% (7.1% - 9.4%), respectively, in patients without N treatment, and 70.8% (62.4% - 77.7%), 32.8% (25.1% - 40.7%) and 11.7% (8.0% - 17.7%) in patients with N treatment. The median OS with N was 22.4 m (13.5-39.5 m) and for patients without was 22.1 m (11.6 - 45.8 m). The OS at 6, 12 and 24 m was 98.6% (94.5% - 99.6%), 80.7% (73.2% - 86.4%) and 45.5% (36.9% - 53.7%), respectively in patients with N and 93.2% (92.0% - 94.1%), 73.9% (72.0% - 75.7%), and 47.1% (44.9% - 49.3%) in patients without.


The results of our analysis described the largest and most comprehensive series of NS NSCLC in the European population. Most patients included in the analysis were men and former or current smokers. The survival probability at 6, 12 and 24 months is slightly better in patients treated with nintedanib versus the overall population.

Clinical trial identification


Legal entity responsible for the study

Fundacion GECP.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.